Irritable Bowel Syndrome Treatment Market

Irritable Bowel Syndrome Treatment Market Outlook (2024 to 2034)

The global irritable bowel syndrome treatment market value was around US$ 2,744.9 million in 2019. Following the year 2019, several private players have surfaced with specialized and effective remedies for irritable bowel syndrome as well as inflammatory bowel disease.

The growing prevalence of irritable bowel syndrome (IBS) is the key factor driving the demand for IBS medication programs along with IBS natural remedies. In 2024, the net worth of revenue incurred from adopting irritable bowel syndrome treatment products and services is expected to be around US$ 4,076.1 million.

The need for efficient IBS therapy, as well as IBS counseling services, is expected to increase with the rising frequency of irritable bowel syndrome. According to the analysis of the market trends by Fact.MR, the demand for irritable bowel syndrome treatment is expected to progress at a CAGR of 8.7% between 2024 and 2034. By following this lucrative growth rate, the net valuation of the industry is expected to reach up to US$ 9,355.4 million by the end of 2034.

Irritable Bowel Syndrome Treatment Market Trends and Analysis

Personalized medicine and medical research advancements have significantly transformed the business model of treatment providers in the last few years. Customizing care to each patient's unique profile is currently an emerging trend, which has aided in improving both patient outcomes and treatment efficacy. Likewise, the introduction of a holistic approach to IBS is expected to fuel the demand for irritable bowel syndrome treatment services in the coming days.

The irritable bowel syndrome treatment industry outlook is evolving rapidly nowadays as a result of the increased use of telemedicine and mobile apps for the delivery of IBS therapy. To improve patient accessibility, providers use remote consultations and virtual therapies, especially when treating chronic diseases like IBS. So, the growing popularity of services like IBS virtual therapy and cognitive behavioral therapy for IBS is anticipated to boost the market demand further in the coming days.

Report Attributes	Details
Estimated Market Value (2024E)	US$ 4,076.1 million
Forecasted Market Value (2034F)	US$ 9,355.4 million
Global Market Growth Rate (2024 to 2034)	8.7% CAGR
Fiber Supplements Segment Growth Rate (2024 to 2034)	9.6% CAGR
Irritable Bowel Syndrome with Diarrhea Segment Growth Rate (2024 to 2034)	10.3% CAGR
Retail Pharmacies Segment Growth Rate (2024 to 2034)	9.4% CAGR
North America Market Share (2024)	8.8%
East Asia Market Share (2024)	7.3%
Key Companies Profiled	Takeda Pharmaceutical Company Limited Pfizer, Inc. Abbott Laboratories Novartis AG AstraZeneca PLC Ironwood Pharmaceuticals Inc. and Allergan Plc Bausch Health Companies Inc. GlaxoSmithKline, Plc. Lexicon Pharmaceuticals, Inc. Sucampo Pharmaceuticals, Inc.

What is the Ongoing Trend Driving the Global Irritable Bowel Syndrome Treatment Market Growth?

“IBS Trigger Foods and Hypnotherapy for IBS Treatment are the Emerging Trends”

Behavioral and psychological therapies for irritable bowel syndrome treatment have come a long way and are expected to improve further with a better understanding of the causes and symptoms of the disease. It has prompted a higher recognition of the link between IBS and mental health, and medical professionals are prescribing stress management techniques and cognitive-behavioral therapy (CBT) more these days.

Recently, the involvement of the microbiota in irritable bowel syndrome was clarified by the research on the connection between gut microbiome and IBS. So, to enhance results, treatment providers use this information in their therapeutic techniques and offer a low FODMAP diet that focuses on gut microbiota balance.

Country-wise Insights

Country	Regional Market CAGR (2024 to 2034)
United States	8.8% CAGR
South Korea	7.9% CAGR

What is the Adoption Rate of Irritable Bowel Syndrome Treatment Methods in East Asia?

“Surging Patients with Irritable Bowel Syndrome Driving the Market in China”

In Asia, demand for IBS management and treatment services has been brought on by patients' growing knowledge about the availability of professional help for managing and relieving IBS symptoms. In 2024, the net worth of all the irritable bowel syndrome treatment industries operating in the East Asian countries of China, Japan, and South Korea is estimated to be around US$ 542 million.

China, with a share of 63.5% of the East Asia market in 2024, emerged as a lucrative country for irritable bowel syndrome treatment products and service providers operating in the region. As the relationship between diet and IBS symptom relief is becoming widely acknowledged in the country, dietary strategies are increasingly emphasized in the treatment regimens.

According to the market estimates by Fact.MR, the net worth of total business, including IBS probiotic supplements, is expected to be around US$ 344 million in 2024. Meanwhile, South Korea is expected to witness a greater CAGR of 7.9%, and Japan is expected to follow China with a CAGR of 7.1% during this period.

Why is the United States Dominating the Global Irritable Bowel Syndrome Treatment Market?

“Greater Awareness of Patients and a Higher Demand for Personalized Treatment”

The market revenue generated in the North America irritable bowel syndrome (IBS) treatment market is estimated to be around US$ 1,722 million in 2024. Personalized IBS treatment solutions are driving the North American market as patient-centric care models are in higher demand in the United States and Canada.

The United States contributes nearly 89.2% of the North American market share, and the net valuation of this regional market is estimated to be around US$ 1,536 million in 2024. Market participants in the United States take into account the requirements, preferences, and lifestyle aspects of each patient, with an emphasis on a patient-centered and holistic approach.

For instance, Ardelyx, a biopharmaceutical company based in the United States, received approval for IBSRELA, a tenapanor medication used for the treatment of irritable bowel syndrome, in 2021.

The adoption of irritable bowel syndrome treatment services in Mexico is growing faster, and the regional market is anticipated to follow a CAGR of 8.9% through 2034, concluding at a valuation of US$ 92 million. On the other hand, the irritable bowel syndrome market in Canada is poised to witness a year-on-year growth rate of 8.7% and reach a valuation of 339 million by 2034.

Category-wise Insights

Which are the Popular Products of Irritable Bowel Syndrome Treatment Market?

“Fiber Supplements are Gaining More Traction than Lubiprostone and Antibiotics”

Among the different types of products available in the present market, lubiprostone is a sought-after treatment solution for irritable bowel syndrome patients. Currently, this segment captures around 22.4% of the total market share and is estimated to generate a revenue of around US$ 894.8 million in 2024. On the other hand, fiber supplements are observed to be growing at a faster rate as an effective treatment for irritable bowel syndrome diseases.

Leading market participants are now forming alliances with medical specialists that guarantee a comprehensive strategy that considers many facets of IBS treatment, including fiber supplements. Healthcare professionals also keep up with new supplement developments and incorporate them into thorough treatment plans. The fiber supplement segment is projected to increase with a CAGR of 9.6% between 2024 and 2034.

What is an effective way to distribute irritable bowel syndrome treatment products?

“Network of Retail Pharmacies Currently Contribute for One-Third of the Market Sales”

Based on the different distribution channels for irritable bowel syndrome treatment products, the retail pharmacies constitute the leading segment of the market. In 2024, the total revenue generated by this segment is expected to be nearly US$ 1,276.2 million. With the advancement in pharmaceutical research, the development of new drugs for the treatment of IBS is expected to expand the share of retail distribution channels further. Over the next ten years, the retail pharmacies segment is predicted to expand at a CAGR of 9.4% to reach a valuation of US$ 3,123.8 million.

Competitive Landscape

The global network of irritable bowel syndrome treatment service providers is gradually becoming competitive with the entry of players focused on other healthcare services earlier. In recent years, small-scale market players, particularly in emerging economies, have become prominent with the growing healthcare demands of people with irritable bowel syndrome.

Recent Developments by Irritable Bowel Syndrome Treatment Industry Participants

• In March 2021, Abbott Laboratories and the Nutrition Society of India teamed up to present clinical dietary advice tailored specifically for the Indian market in an effort to increase awareness among patients with gastrointestinal disorders. Functional constipation, peptic ulcers, chronic pancreatitis, and irritable bowel syndrome are examples of GI disorders that are expected to create enough opportunities for Abbott to expand its business in the country.
• In June 2022, Ferring B.V., a biopharmaceutical company, revealed that it has partnered with I-MAB Biopharma Limited, a globally recognized biopharma company focused on innovation. The two companies entered into a partnership to advance the development of Olamkicept, a selective interleukin-6 (IL-6) trans-signaling inhibitor for treating inflammatory bowel disease (IBD) and associated inflammatory conditions.

Key Segments Covered by Irritable Bowel Syndrome Treatment Industry Survey Report

• By Product Type:

  • Fiber Supplements
  • Anti-Diarrheal
  • Anticholinergic and Antispasmodic
  • Antidepressant
  • Antibiotics
  • Alosetron
  • Lubiprostone
  • Linaclotide
  • NHE3

• By Indication:

  • Irritable Bowel Syndrome with Constipation
  • Irritable Bowel Syndrome with Diarrhea
  • Irritable Bowel Syndrome with Alternating Constipation and Diarrhea

• By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies and Stores
  • Hypermarkets and Supermarkets
  • Other Distribution Channels

• By Region:

  • North America
  • Europe
  • Latin America
  • East Asia
  • South Asia & Oceania
  • The Middle East & Africa (MEA)